GH Form 144: 2,000-Share Sale Notice; Prior 4,000-Share Sale Reported
Rhea-AI Filing Summary
Guardant Health, Inc. (GH) Form 144 shows a proposed Rule 144 sale and recent related transactions by insiders. The filer reports intent to sell 2,000 common shares through Charles Schwab with an aggregate market value of $123,510 and an approximate sale date of 08/21/2025 on NASDAQ. Those 2,000 shares were acquired on 10/01/2024 via the lapse of restricted stock as equity compensation. The filing also discloses a prior sale by Kumud Kalia of 4,000 shares on 06/03/2025 for gross proceeds of $185,562. The notice includes the standard insider representation regarding material undisclosed information and potential 10b5-1 plan disclosure.
Positive
- Full Rule 144 disclosure provided with acquisition dates, broker, and planned sale date indicating regulatory compliance
- Transaction transparency includes both the intended sale and a prior sale with gross proceeds, aiding investor visibility
Negative
- Insider selling activity (2,000 shares planned; 4,000 previously sold) could be viewed negatively by some investors as reduced insider ownership
Insights
TL;DR: Routine Rule 144 notice disclosing an insider sale of recently vested restricted shares and a prior sale by a named individual.
This filing documents compliance with Rule 144 for an intended sale of 2,000 shares acquired through a restricted stock lapse on 10/01/2024, to be executed via Charles Schwab on 08/21/2025. It also reports a separate, completed sale of 4,000 shares by Kumud Kalia on 06/03/2025 for $185,562. From a compliance perspective, the filing provides essential transaction dates, acquisition nature, and broker details required under Rule 144; no material undisclosed information is asserted by the seller.
TL;DR: Insider selling of vested equity is disclosed; context suggests routine liquidity rather than employment or control change.
The notice shows equity compensation vesting followed by a planned sale, which is a common executive/employment-related liquidity event. The designations and amounts are clear: 2,000 shares from restricted stock lapse and a prior 4,000-share sale. The filing includes the standard attestation about no material nonpublic information and mention of potential 10b5-1 plans, indicating awareness of trading-plan safe harbors.
FAQ
What does Guardant Health's Form 144 disclose for GH?
How were the 2,000 shares acquired per the Form 144?
Were there any recent related sales reported?
Which broker is handling the proposed sale?
Does the filer state there is any undisclosed material information?